PAUL CASTRO: Open Payments
NPI 1427769918 · DUARTE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$681 in 22 payments from 8 companies in 2025. Trend: 2023 $367 · 2024 $544 · 2025 $681
Food & beverage: $457Education: $224
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 11 | $307 |
| SOBI, INC | 2 | $118 |
| Daiichi Sankyo Inc. | 4 | $98 |
| Alexion Pharmaceuticals, Inc. | 1 | $37 |
| GlaxoSmithKline, LLC. | 1 | $32 |
| GENZYME CORPORATION | 1 | $31 |
| Syndax Pharmaceuticals, Inc. | 1 | $30 |
| Melinta Therapeutics, LLC | 1 | $29 |
Products named: Cresemba, Vanflyta, Vyloy, Xospata, Gamifant, OJJAARA, Rezzayo.
Industry payments across CA — which companies pay providers there.
